BACKGROUND: The aim of this study was to evaluate the concentration of cefazolin in adipose tissue of patients undergoing bariatric surgery. METHODS: Eighteen patients undergoing bariatric surgery were evaluated during the period from October 2011 to May 2012. All patients had a dosage schedule of antibiotic prophylaxis with cefazolin administered as follows: first, 2 g in anesthetic induction, followed by continuous infusion of 1 g diluted in 250 ml of saline solution. Adipose samples, collected soon after the incision (initial) and before the skin synthesis (final), were analyzed using reverse phase high-pressure liquid chromatography. The level of significance adopted was 5 %. RESULTS: The cefazolin concentration in the adipose tissue samples at the beginning of surgery was an average of 6.66 ± 2.56 ug/ml. The mean concentration before the skin synthesis was 7.93 ± 2.54 ug/ml. Patients with BMI < 40 kg/m(2) had higher initial and final sample concentrations of cefazolin than patients with BMI ≥ 40 kg/m(2). There was no surgical site infection (SSI) in any of the patients. CONCLUSIONS: In bariatric surgeries, addition of a 1 g increase of cefazolin, administered through continuous intravenous infusion, to the currently recommended dose of 2 g administered in anesthetic induction provided a concentration in the adipose tissue above the minimum inhibitory concentration (MIC) of the main causal agents of SSI. An inverse correlation between BMI and concentration of cefazolin in adipose tissue was observed.
BACKGROUND: The aim of this study was to evaluate the concentration of cefazolin in adipose tissue of patients undergoing bariatric surgery. METHODS: Eighteen patients undergoing bariatric surgery were evaluated during the period from October 2011 to May 2012. All patients had a dosage schedule of antibiotic prophylaxis with cefazolin administered as follows: first, 2 g in anesthetic induction, followed by continuous infusion of 1 g diluted in 250 ml of saline solution. Adipose samples, collected soon after the incision (initial) and before the skin synthesis (final), were analyzed using reverse phase high-pressure liquid chromatography. The level of significance adopted was 5 %. RESULTS: The cefazolin concentration in the adipose tissue samples at the beginning of surgery was an average of 6.66 ± 2.56 ug/ml. The mean concentration before the skin synthesis was 7.93 ± 2.54 ug/ml. Patients with BMI < 40 kg/m(2) had higher initial and final sample concentrations of cefazolin than patients with BMI ≥ 40 kg/m(2). There was no surgical site infection (SSI) in any of the patients. CONCLUSIONS: In bariatric surgeries, addition of a 1 g increase of cefazolin, administered through continuous intravenous infusion, to the currently recommended dose of 2 g administered in anesthetic induction provided a concentration in the adipose tissue above the minimum inhibitory concentration (MIC) of the main causal agents of SSI. An inverse correlation between BMI and concentration of cefazolin in adipose tissue was observed.
Authors: Leo Pevzner; Morgan Swank; Candace Krepel; Deborah A Wing; Kenneth Chan; Charles E Edmiston Journal: Obstet Gynecol Date: 2011-04 Impact factor: 7.661
Authors: Vanessa P Ho; David P Nicolau; Gregory F Dakin; Alfons Pomp; Barrie S Rich; Christopher W Towe; Philip S Barie Journal: Surg Infect (Larchmt) Date: 2012-02-08 Impact factor: 2.150
Authors: Teena Chopra; Jing J Zhao; George Alangaden; Michael H Wood; Keith S Kaye Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2010-06 Impact factor: 2.217
Authors: Erin Koopman; David E Nix; Brian L Erstad; Michael J Demeure; Melinda M Hayes; John T Ruth; Kathryn R Matthias Journal: Am J Health Syst Pharm Date: 2007-09-15 Impact factor: 2.637
Authors: Jason A Roberts; Jennifer Paratz; Elizabeth Paratz; Wolfgang A Krueger; Jeffrey Lipman Journal: Int J Antimicrob Agents Date: 2007-04-17 Impact factor: 5.283
Authors: April Barbour; Stephan Schmidt; W Robert Rout; Kfir Ben-David; Olaf Burkhardt; Hartmut Derendorf Journal: Int J Antimicrob Agents Date: 2009-05-02 Impact factor: 5.283
Authors: Manjunath P Pai; Jeffrey P Norenberg; Tamara Anderson; Diane W Goade; Keith A Rodvold; Robert A Telepak; Renee-Claude Mercier Journal: Antimicrob Agents Chemother Date: 2007-06-04 Impact factor: 5.191
Authors: Rochelle L Ryan; Dwane Jackson; George Hopkins; Victoria Eley; Rebecca Christensen; Andre A J Van Zundert; Steven C Wallis; Jeffrey Lipman; Suzanne L Parker; Jason A Roberts Journal: Antimicrob Agents Chemother Date: 2022-06-28 Impact factor: 5.938
Authors: Eduardo Celia Palma; Nelson Guardiola Meinhardt; Airton Tetelbom Stein; Isabela Heineck; Maria Isabel Fischer; BibianaVerlindo de Araújo; Teresa Dalla Costa Journal: Pharm Res Date: 2018-04-11 Impact factor: 4.200